Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Related Articles
Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma
David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.
Acalabrutinib/Chemotherapy Poised to Be Effective in High-Risk MCL
Acalabrutinib improves efficacy in high-risk patients like those with TP53 mutations, those with complex cytogenetics, and those with high proliferative rates in MCL.
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer
AbstractIntroduction. The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR)
Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission
The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions
Cell-based therapies have become integral to the routine clinical management of hematologic malignancies. Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in immunogenic solid tumors, such…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC
Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.
17th Annual Hematologic Malignancies Demystified 2025 | Virtual
Register now for HMD 2025 and explore groundbreaking advancements in hematology. Stay informed with the latest innovations shaping the future of hematology research presented at…
